Drugs / ProDiax-23
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04875858 | May 2021 → Apr 2022 | pneumococcal infection | Korea University Guro Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02079207 Comparator | Dec 2013 → Oct 2014 | pneumococcal infection | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prodiax-23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02079207 ↗ |
| Known as | PPSV23 | “Drug: ProDiax-23 (PPSV23)” NCT04875858 ↗ |
| Modality | Vaccine | “23-valent Pneumococcal Polysaccharide Vaccine” NCT04875858 ↗ |